Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Lassman, Andrew B., Pugh, Stephanie L., Gilbert, Mark R., Aldape, Kenneth D., Geinoz, Sandrine, Beumer, Jan H., Christner, Susan M., Komaki, Ritsuko, DeAngelis, Lisa M., Gaur, Rakesh, Youssef, Emad, Wagner, Henry, Won, Minhee, Mehta, Minesh P.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762006/
https://ncbi.nlm.nih.gov/pubmed/25758746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov011
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares